This compound, with CAS number 171596-43-3, is chemically identified as (6R,12aR)-6-(benzo[d][1,3]dioxol-5-yl)-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4(6H,7H)-dione. It is a known impurity associated with the active pharmaceutical ingredient (API) Tadalafil. Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used for the treatment of erectile dysfunction and symptoms of benign prostatic hyperplasia. As a specified impurity, this compound is critical in the pharmaceutical quality control process. It is manufactured and supplied as a certified reference standard (CRS) or impurity standard for use in analytical testing. Its primary application is in the development and validation of analytical methods (e.g., HPLC, LC-MS) to monitor and control the levels of this impurity in Tadalafil drug substances and finished drug products, ensuring they meet stringent pharmacopeial (e.g., USP, EP) and regulatory safety specifications. The availability of this high-purity impurity standard is essential for pharmaceutical companies and testing laboratories to comply with Good Manufacturing Practice (GMP) guidelines, assess drug stability, and guarantee the safety, efficacy, and quality of the final medicinal product.